25-NSE ·Filed May 28, 2026

AZN

ASTRAZENECA PLC
NEUTRAL
Impact 2/10
Horizonimmediate Processed4mo ago SEC0000876661-26-000484
Notable filing: 25-NSE
Actionable Insight • Neutral

No action required for AZN common stock holders. This filing relates solely to the delisting of a matured bond guarantee and has no read-through for AstraZeneca's equity, credit profile, or operations. Monitor for any future cross-filings if the company restructures its debt guarantees, but this event is routine.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d ⚠ clustered
AZN ▼ -10.53% at T+60d
NEUTRAL call ✗ call lost -10.53% · α vs SPY -12.01% · entry $185.34 → $165.82
Entry anchored
May 28, 2026
via day open
T+1d
+0.08%
call +0.08% · α -0.16%
$185.49
settled 4mo ago
T+5d
-1.94%
call -1.94% · α -2.25%
$181.75
settled 4mo ago
T+20d
+0.19%
call +0.19% · α +2.88%
$185.68
settled 3mo ago
T+60d
-10.53%
call -10.53% · α -12.01%
$165.82
settled 6w ago

Price Chart

Loading chart...

Executive Summary

The NYSE filed a Form 25-NSE to delist a guarantor of AstraZeneca's 1.200% Notes due 2026, following the notes' redemption at maturity on May 28, 2026. This is a routine administrative delisting of a matured debt security, not the company's common stock, and has no financial or operational impact on AstraZeneca PLC.

Key Facts

  • Form 25-NSE filed by NYSE on May 28, 2026 to delist and deregister the guarantor of AstraZeneca's 1.200% Notes due 2026
  • The notes were redeemed or paid at maturity on May 28, 2026, per 17 CFR 240.12d2-2(a)(2)
  • Delisting effective at the opening of business on June 8, 2026
  • The security was suspended from trading on May 28, 2026
  • This affects only the specific debt security (guarantor of 1.200% Notes due 2026), not AZN common stock
  • AstraZeneca's common stock (AZN) remains listed on the NYSE

Financial Impact

No material financial impact — relates to a matured debt security, not the company's equity

Risk Factors

  • None — this is a standard post-maturity administrative filing with zero impact on AZN equity

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (36 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
25-NSE Filing (Primary)0000876661-26-000484
Document: 0000876661-26-000484-index.html0000876661-26-000484
Document: 0000876661-26-000484.txt0000876661-26-000484
54 reports for AZN
Performance horizon
67% Hit rate 20 of 30 directional calls best @ T+60▲ +13.65%Jul 6, 2026
Filters
Rows
Reports for AZN — sortable, filterable
TypeNow
Sep 15, 2026
17d ago
6-K
NEUTRAL ★ 2/10
$161.85 $168.37▲ +4.03%▲ +1.90%$156.93 (−3.04%)
Sep 14, 2026
18d ago
6-K
BEARISH ★ 5/10
$163.78 $168.10▼ −2.64%▼ −2.53%$156.93 (+4.18%)
Sep 8, 2026
24d ago
6-K
BULLISH ★ 7/10
$160.04 $161.85▲ +1.13%▲ +2.25%$156.93 (−1.94%)
Sep 1, 2026
4w ago
6-K
NEUTRAL ★ 1/10
$162.22 $156.94▼ −3.25%▼ −3.33%$156.93 (−3.26%)
Sep 1, 2026
4w ago
6-K
NEUTRAL ★ 1/10
$162.22 $156.94▼ −3.25%▼ −3.33%$156.93 (−3.26%)
Sep 1, 2026
4w ago
6-K
NEUTRAL ★ 3/10
$162.47 $156.94▼ −3.40%▼ −3.49%$156.93 (−3.41%)
Sep 1, 2026
4w ago
6-K
BULLISH ★ 7/10
$162.22 $156.94▼ −3.25%▼ −3.33%$156.93 (−3.26%)
Sep 1, 2026
4w ago
6-K
NEUTRAL ★ 5/10
$162.22 $156.94▼ −3.25%▼ −3.33%$156.93 (−3.26%)
Sep 1, 2026
4w ago
6-K
BULLISH ★ 7/10
$162.47 $156.94▼ −3.40%▼ −3.49%$156.93 (−3.41%)
Aug 31, 2026
4w ago
Court Ruling
BEARISH ★ 3/10
$162.13 $159.95▲ +1.34%▲ +1.20%$156.93 (+3.20%)
Showing 10 of 54

US Market Status

Market Open — Closes in 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access